For example, the first FDA-approved double-stranded siRNA therapeutics, patisiran (ONPATTROTM), encapsulated in lipid nanoparticles for delivery to hepatocyte, is used to treat the polyneuropathy of hereditary transthyretin (TTR)-mediated amyloidosis (hATTR) in adults [137]. This evidence concerns the gene TTR and amyloidosis.